rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    XBI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Biotech ETFs Face Crucial FDA Week as Drug Catalysts Loom - State Street SPDR S&P Biotech ETF (ARCA:XBI)
      Nov 16BenzingaSTTXBI
      IYH and XBI: Two Distinct Paths to Investing in Healthcare | The Motley Fool

      XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.

      Nov 7The Motley FoolIYHXBI
      Decoding Healthcare ETFs: Different Sectors, Different Strategies | The Motley Fool

      RSPH offers broader sector diversification with lower volatility, while XBI delivers higher short-term gains but with steeper drawdowns.

      Nov 7The Motley FoolRSPHXBI
      Is State Street SPDR S&P Insurance ETF (KIE) a Strong ETF Right Now?
      Oct 22Yahoo FinanceKBWPIAKKBEKCEKREXBI
      Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
      Oct 21Yahoo FinanceXBIXHS
      Is State Street SPDR S&P Telecom ETF (XTL) a Strong ETF Right Now?
      Oct 5Yahoo FinanceSTTXBIXNTKXPHXRTXSDXTLXTN
      Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech | The Motley Fool

      Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.

      Oct 5The Motley FoolSTTFHLCXBI
      Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals | The Motley Fool

      XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown.

      Oct 4The Motley FoolSTTXBIXPH
      Big Pharma Got Its Tariff Exemption. The Biotech ETF Barely Blinked
      Sep 30Yahoo FinanceXBI
      Is State Street SPDR S&P Semiconductor ETF (XSD) a Strong ETF Right Now?
      Sep 30Yahoo FinanceSMHSOXXSTTXBIXNTKXPHXSD
      Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

      Smart Beta ETF report for XBI

      Sep 29Yahoo FinanceSTTXBI
      Biotech ETF XBI Hits a Rate Wall as 40+ Catalysts Approach - State Street SPDR S&P Biotech ETF (ARCA:XBI)

      B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.

      Sep 25BenzingaXBI
      Economy Grew 63%, 30-Year Treasury Lost 45% Since 2020 - State Street SPDR S&P Biotech ETF (ARCA:XBI), iS

      Over six years, U.S. nominal GDP rose 63% while the 30-year Treasury fell 60%. Are investors positioned for a surge in stocks and yields?

      Sep 25BenzingaSTTXBI
      Biotech: The Party's Over, The Top Is In (NYSEARCA:XBI)

      XBI may have peaked after a 60% rally as tailwinds fade, equity supply hits cycle highs, and momentum rolls over. Click to read more about XBI's sell rating.

      Sep 24Seeking AlphaXBI
      VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? | The Motley Fool

      VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.

      Sep 22The Motley FoolXBI
      Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
      Sep 22BenzingaARKGQNDXFBTXBI
      Is State Street SPDR S&P Transportation ETF (XTN) a Strong ETF Right Now?

      Smart Beta ETF report for XTN

      Sep 22Yahoo FinanceFTXNFTXRXBIXHBXRTXTLXTN
      Is State Street SPDR S&P Retail ETF (XRT) a Strong ETF Right Now?

      Smart Beta ETF report for XRT

      Sep 18Yahoo FinanceRTHSTTRSPSXARXBIXHBXNTKXPHXRTXTN
      Is State Street SPDR S&P Homebuilders ETF (XHB) a Strong ETF Right Now?

      Smart Beta ETF report for XHB

      Sep 8Yahoo FinanceSTTKBEXARXBIXHBXHSXPHXRTXSD
      XBI: Big Pharma Can Keep The 76% Rally Going (NYSEARCA:XBI)

      Buy XBI? Get outlook for the SPDR S&P Biotech ETF—8%–14% return target, M&A tailwinds, key risks, and volatility factors.

      Sep 5Seeking AlphaXBI
      Is State Street SPDR S&P Software & Services ETF (XSW) a Strong ETF Right Now?
      Sep 3Yahoo FinanceIGVSTTIGPTXARXBIXESXHSXNTKXRTXSDXSW
      Analysts See Drastic Change For This Particular Part Of Healthcare

      State Street SPDR S&P Biotech ETF is hovering around a buy point after breaking out. The fund is one of the holdings in IBD Leaderboard.

      Aug 24Investor's Business DailyXBI

      This is the newest page. Registered accounts read further back.